Galderma agrees $1.5bn takeover of US skincare brand

US$1.5 billion in cash will bring California-based ZO Skin Health under the control of Swiss skincare group Galderma, in one of the company’s largest moves to expand its medical skincare business. Galderma announced the agreement on October 14, 2026, saying the acquisition would support growth in products distributed through doctors.

The deal covers 100% of ZO Skin Health. Galderma will fund it through existing cash reserves and bank financing, rather than issuing shares. The sellers include funds managed by Blackstone Tactical Opportunities and the family of ZO founder Zein Obagi, a dermatologist who established the brand in the United States.

The transaction still requires regulatory approval and other customary closing conditions. Galderma expects it to close in the fourth quarter of 2026 or early 2027. The timing places the deal within a period when the Zug-headquartered company is continuing to build a broader platform spanning prescription-adjacent skincare, aesthetic treatments and consumer health products.

For Switzerland, the acquisition adds another international asset to a company that has made its headquarters in the canton of Zug while competing in a global market led by specialist brands and physician networks.

Three major skincare brands will sit within Galderma’s portfolio after the transaction: ZO Skin Health, Alastin and Cetaphil. The company describes ZO and Alastin as complementary rather than overlapping businesses, with each focused on a different point in the medical and aesthetic skincare journey.

ZO Skin Health sells medically oriented products for daily routines. Its formulations include retinol and acids, and the brand is built around structured regimens often recommended through professional channels. Alastin focuses on regenerative skincare, using peptides to support the skin before and after dermatological or aesthetic procedures. Cetaphil gives Galderma a larger presence in everyday skincare and sensitive-skin care.

That combination could allow Galderma to approach specialists with a wider set of products, from routine treatment to preparation for procedures and post-treatment care. The company says the expanded portfolio will create growth opportunities among dermatologists, plastic surgeons and other healthcare professionals.

ZO’s medical positioning also fits Galderma’s broader strategy. The group has invested in products and training linked to dermatology and aesthetic medicine, sectors where clinical credibility and relationships with practitioners can shape purchasing decisions. The acquisition gives it another established brand with a specialist identity and a defined treatment framework.

The first full financial year after completion is expected to be earnings-neutral on an adjusted EPS basis, according to Galderma. The company also expects a slight dilution of its adjusted EBITDA margin in 2027, followed by a return to approximately the group average from 2028.

Those projections show how Galderma is framing the acquisition: as a strategic expansion that will take time to contribute fully to profitability. The all-cash structure gives the sellers a clear exit and avoids shareholder dilution, while the use of bank financing adds debt funding to the transaction. Galderma did not disclose further financing terms in the announcement cited by Swissinfo.

The company will need to integrate ZO Skin Health while preserving the brand’s appeal among physicians and patients. ZO is headquartered in Irvine, California, and its commercial base is rooted in the United States. Galderma, meanwhile, operates internationally from its Swiss base and sells across several healthcare and skincare categories.

Regulatory review remains the immediate checkpoint. Once approvals are secured, execution will determine whether Galderma can expand distribution without weakening ZO’s specialist positioning. The projected margin path gives investors a clear timetable for judging the purchase, with 2027 expected to carry the initial pressure and 2028 set as the point when profitability should normalise.

ZO Skin Health strengthens Galderma’s position with doctors and aesthetic specialists, an area the Swiss group has been developing alongside its skincare business. The acquisition follows Galderma’s wider engagement with medical professionals, including training initiatives linked to injectable treatments and aesthetic procedures.

The company’s existing Alastin brand is focused on products used around dermatological and aesthetic interventions. ZO adds a broader daily-care proposition based on structured routines and active ingredients such as retinol and acids. Together, the brands could give practitioners more options for recommending products before, during and after treatment, while keeping Galderma’s commercial relationship with clinics at the centre.

That model matters in Switzerland as well as abroad. Galderma is headquartered in the canton of Zug, but its growth depends on international sales and specialist networks rather than the domestic market alone. The company’s expanding portfolio reflects the globalisation of dermatology, where product companies increasingly connect clinical services, professional training and at-home care.

The deal will also test Galderma’s ability to manage brands with different identities. ZO Skin Health was founded by dermatologist Zein Obagi and has built its reputation around physician-guided skincare. Preserving that credibility will be central as the company brings the brand into a larger Swiss-led group.

The transaction is expected to close by early 2027, giving Galderma a defined period to secure approvals and prepare the integration of ZO Skin Health. The group’s stated ambition is to cover more of the medical skincare market, from daily routines to products associated with aesthetic and dermatological procedures.

The financial milestones are equally clear. Galderma expects no adjusted EPS impact in the first full year after closing, a slight adjusted EBITDA margin dilution in 2027 and a return to roughly the group average from 2028. Those forecasts will become the first benchmarks for assessing whether the acquisition delivers the growth and operating benefits management anticipates.

For the Swiss group, the purchase expands an international platform built from a Zug base. It also increases exposure to the United States, where ZO was founded and remains headquartered in Irvine. The combined business will have to coordinate manufacturing, distribution, regulatory compliance and professional education across markets with different rules and healthcare systems.

The immediate story is therefore the price and the timetable. The longer test will be whether Galderma can keep ZO’s physician-led identity while using its own global scale. If it succeeds, the deal will give the company a broader route into clinics and consumers. If integration proves difficult, the promised margin recovery from 2028 will face closer scrutiny.